MilliporeSigma Acquires Mirus Bio to Enhance Viral Vector Production

The purchase of Mirus Bio by MilliporeSigma's Life Science division has closed for an estimated $600 million, subject to regulatory clearances and the satisfaction of other normal closing conditions.The purchase is a calculated move towards the company's goal of providing solutions for each stage of the production of viral vectors. Additionally, it reaffirms the business's dedication to helping clients advance gene and cell treatments from preclinical to commercial manufacturing.

"Impressive prospects exist for delivering novel therapeutic interventions to patients through innovative modalities such as gene and cell therapies," stated Sebastian Arana, Head of Process Solutions at Merck KGaA's Life Science division in Darmstadt, Germany. "Mirus Bio's cutting-edge technology, together with our depth of experience in bioprocessing and diverse portfolio, will allow us to provide comprehensive solutions throughout the viral vector value chain and assist with meet the growing demand for these life-saving therapies.”

Transfection reagent development and marketing, including TransIT-VirusGEN, is the area of expertise for Mirus Bio. These materials are essential to the creation of gene treatments based on viral vectors. With the purchase of the industry-leading transfection reagents from Mirus Bio, MilliporeSigma can now provide an integrated viral vector production solution in addition to strengthening its upstream range.